Biotechs are strategically using Australia's speed to their advantage. By starting a Phase 1 trial in Australia in parallel with a US IND application, they can collect early data from healthy volunteers and a small patient cohort. This data can then be used to strengthen the US filing, potentially justifying a higher starting dose or an improved trial design.

US biotechs increasingly use sites like Australia to accelerate development, as Create Medicines did by moving from concept to clinic in under 12 months. What was once viewed with suspicion is now a key strategy to generate data faster and more cheaply, competing with the speed of China's ecosystem.

The US regulatory regime for early clinical trials is so slow that companies are opting for more efficient systems, like Australia's local IRB-based approval. This offshoring of initial research puts the US at a global competitive disadvantage in generating crucial early data.

The global landscape for early-stage clinical trials is shifting, with the U.S. at risk of falling behind. Australia has established itself as a trendsetter and a primary destination for first-in-human studies, while China is accelerating development by leveraging "China speed" and a higher regulatory risk tolerance.

The challenge from China in biotech isn't just about their progress; it's a mirror reflecting America's self-inflicted inefficiencies. The U.S. has become too slow for early-stage trials, lagging even Australia, which has one-tenth the population but runs four times as many first-in-human studies.

Moving first-in-human studies to countries like Australia and China is now a core business strategy, not just a cost-saving measure. It allows U.S. biotechs to navigate a more flexible regulatory environment and accelerate development timelines.

Countries like Saudi Arabia and Brazil are building their biotech sectors by offering a critical asset Western pharma companies struggle to find: diverse patient populations. Access to these demographics for clinical trials provides invaluable data, making these regions strategic partners for global drug development.

For a smaller company, conducting a clinical trial within one country like the UK is highly efficient. It streamlines regulation under one agency (the MHRA), reduces costs, and allows for rapid patient enrollment by leveraging a tight-knit national network of clinical specialists.

Small European countries like Denmark are becoming competitive FIH hubs by optimizing process, not leveraging population. Denmark launched an expedited process targeting 14-day approvals by using a centralized ethics committee that runs its review in parallel with the regulatory assessment, creating a significant speed advantage.